T1	Participants 32 66	negative symptoms of schizophrenia
T2	Participants 540 604	meta-analysis of the pooled results from six double-blind trials
T3	Participants 928 1171	combined patient population treated with 4-8 mg/day of risperidone was 1.43 times more likely to have had a clinical response on the negative symptom subscale than the combined population treated with haloperidol, perphenazine or zuclopenthixo
